ARLG – home

Who We Are

The Antibacterial Resistance Leadership Group (ARLG) consists of more than 50 leading experts working together to combat the antibacterial resistance crisis and improve patient care. We accomplish this goal through a scientific agenda that prioritizes areas of unmet needs, innovates clinical trial design, and informs practice-changing guidelines.

Created in 2013, ARLG receives its funding from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. It is facilitated by the Duke Clinical Research Institute and works under the thought leadership of an executive committee and two principal investigators: Vance Fowler, MD, of Duke University, and Henry “Chip” Chambers, MD, of University of California, San Francisco.

To PRIORITIZE, DESIGN and EXECUTE

clinical research that will reduce the
public heath threat of antibacterial resistance.

Access, review, or consult with us on more than 800 strains for your laboratory research.

Access Strains

Are you an early-stage career investigator? Learn more about our grants and fellowships.

Learn More

KNOWLEDGEABLE

Published
110 manuscripts
with more than 300
co-authors

CAPABLE

Initiated more
than 40 studies at
130 clinical
trials sites

WORLDWIDE

Established in 19
countries with more
than 18,000
participants

Our Publications

The ARLG is committed to sharing research findings to inform practice guidelines that improve patient care. Since 2013, we have published 110 publications, and collaborated with more than 300 co-authors from 150 organizations in 15 countries.

View Our Publications

MASTER-GC

MASTER-GC (Master Protocol – Gonorrhoeae and Chlamydia testing of extragenital specimens) is evaluates the performance of nucleic acid amplification tests for the detection of neisseria gonorrhea and chlamydia trachomatis in extragenital sites. The study uses the MASTERMIND (MASTER protocol for evaluating Multiple INfection Diagnostics), and provides an opportunity for multiple companies to submit a 510K under one protocol. MASTERMIND uses a single subject’s sample(s) to provide(s) clinical trial researchers with the capacity to evaluate multiple diagnostic tests at the same time, realize efficiencies of specimen collection and characterization, and overcome monetary and logistical hurdles.

View All Studies in Progress

man

The RADICAL Study

Antibiotics are drugs that treat infections caused by bacteria, but they do not work on viruses, such as colds and the flu. Taking antibiotics when they are not needed can be harmful and can create drug-resistant bacteria, which is a serious public health issue. Although doctors can use laboratory tests to help identify what’s causing an illness, these tests can be slow, inaccurate, and are often unavailable where patients receive care. Rather than trying to test for the presence of a virus or bacteria, the Rapid Diagnostics in Categorizing Acute Lung Infections (RADICAL) study focuses on how patients respond to the infection.

View All Lay Summaries of Results